A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 23, Issue 1, 2011, Pages 9-13

  El Atat, Fadi ^a   Sarkar, Kunal ^a   Kodali, Visali ^a   Karajgikar, Rucha ^a   Jakkulla, Madhavi ^a   Mares, Angelica ^a   Sharma, Samin ^a   Kini, Annapoorna ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

aspirin resistance; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; THERAPY RESISTANCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; PILOT STUDY; THROMBOCYTE; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; ANGIOPLASTY, BALLOON, CORONARY; ANTITHROMBINS; ASPIRIN; BLOOD PLATELETS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; TICLOPIDINE;

EID: 79954431107     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990;82(3 Suppl):II47-II59.
2. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965. (Pubitemid 36315537)
3. Samara WM, Gurbel PA. The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis 2003;14:65-79. (Pubitemid 36337819)
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in pa-tients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
6. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134. (Pubitemid 17093200)
7. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the pre-vention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
8. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005;46:1 820-1826.
9. Singh M, Williams BA, Gersh BJ, et al. Geographical differences in the rates of an-giographic restenosis and ischemia-driven target vessel revascularization after percu-taneous coronary interventions: Results from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. J Am Coll Cardiol 2006;47:34-39. (Pubitemid 43005161)
10. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopido-grel pretreatment.J Am Coll Cardiol 2004;43:1122-1126. (Pubitemid 38353000)
11. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655. (Pubitemid 34298607)
12. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007. (Pubitemid 27417291)
13. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined as-pirin resistance with a higher risk of recurrent cardiovascular events: A systematic re-view and meta-analysis. Arch Intern Med 2007;167:1593-1599. (Pubitemid 47280339)
14. Sabatine MS, Cannon CP, Gibson CM, et al., for the CLARITY-TIMI 28 investiga-tors. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarc-tion with ST-segment elevation. N Engl J Med 2005;352:1179-1189. (Pubitemid 40397259)
15. Mehta SR, Yusuf S, Peters RJ, et al. The clopidogrel in unstable angina to prevent re-current events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coro-nary intervention: The PCI-CURE study Lancet 2001;358:527-533. (Pubitemid 32772726)
16. Kastrati A, Mehilli J, Schuhlen H, et al. The intracoronary stenting and antithrom-botic regimen-rapid early action for coronary treatment study investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238.
17. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
18. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. American College of Cardiology/Amer-ican Heart Association Task Force on Practice Guidelines. ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A re-port of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:E166-E286. (Pubitemid 43879461)
19. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays implications for aspirin "resistance." J Am Coll Cardiol 2009;53:667-677.
20. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251. (Pubitemid 28153440)
21. Valgimigli M, Campo G, de Cesare N, et al. Tailoring treatment with tirofiban in pa-tients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R) investi-gators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Pa-tients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circu-lation 2009;119:3215-3222.
22. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa re-ceptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-961.
23. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study JACC Cardiovasc Interv 2008;1:649-653.
24. Wiviott SD, Antman EM, Gibson CM, et al., and the TRITON-TIMI 38 investiga-tors. Evaluation of prasugrel compared with clopidogrel in patients with acute coro-nary syndromes: Design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J2006;152:627-635. (Pubitemid 44396884)
25. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:E9-E16.